Chapter 49: Osteoporosis, Menopause & Testosterone Use Flashcards
T Score Results
Normal >=1
Osteopenia (low bone mass) -1 to -2.4
Osteoporosis <= -2.5
Medical Diseases/Conditions that Increase Osteoporosis Risk
Anorexia Diabetes GI Diseases (IBD, Celiac, Gastric Bypass, malabsoprtion syndrome) Hyperthyroidism Hydogonadism in men Menopause RA (autoimmune diseases) Epilepsy HIV/AIDS Parkinson disease
Lifestyle Factors that Increase Osteoporosis Risk
Smoking Excessive Alcohol (>=3 drink/day) Low Ca intake Low Vit D intake Physical Inactivity
Medications that Increase Osteoporosis Risk
Anticonvulsants Aromatase Inhibitors Depo-medroxyprogesterone GnRH agonists Lithium PPIs Steroids (>=5mg/day of prednisone) Thyroid Hormones Heparins Loops, SSRIs TZD
Calcium Recommended Daily Intake
1,000 to 1,200 elemental Ca
Ca Carbonate is 40% elemental
Ca Citrate is 21% elemental
Vitamin D Deficiency
Vit D deficiency <30ng/ml
Vitamin D Deficiency Tx
5,000 - 7,000 iu qd
or
50,000iu qw
Bisphosphonates CI
Hypocalcemia
Inability to stand or sit upright for at least 30 minutes
Bisphosphonates Warnings
Osteonecrosis of the Jaw Atypical Femur fractures Esophagitis, esophageal ulcers, erorsion Hypocalcemia Renal Impairment (do not use of CrCl <35 alendronate or >30 ibandronate/risedronate)
Bisphosphonates SE
Dyspepsia Dysphagia Heartburn N/V Hypocalcemia
Alendronate Dosing
10mg/day or 70mg/week
Risedronate
(actonel/atelvia)
5mg po qd
35mg po qweek
150mg q month
Ibandronate
(Boniva)
150mg po q month
Injectable Bisphosphonates CI
Hypocalcemia
Injectable Bisphosphonates Warnings
Same as Po
Renal impairment (monitor SCr)
Injectable Bisphosphonates Notes
Preferred if esophagitis is present (due to risk of esophageal cancer)
Ibandronate Injections
3mg q3months
Zoledronic Acid
(Reclast)
5mg Q year
Bisphosphonates MOA
Work by increasing bone density by inhibiting osteoclast activity and bone resorption.
Reduce vertebral and hip fracture risk (except ibandronate only vertebral)
1st line for prevention of osteoporosis
Raloxifene MOA
estrogen agonist/antagonist (SERM) that decreases bone resorption